F. Stephen Hodi

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics